Domov › Epiteliálny karcinóm vaječníkov › Ohio
Klinické štúdie Epiteliálny karcinóm vaječníkov v štáte Ohio
10 štúdií pre Epiteliálny karcinóm vaječníkov hľadá účastníkov v zariadeniach v štáte Ohio.
Mestá v štáte Ohio
Oficiálny text štúdie (anglicky)
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Cleveland
Prebieha náborFáza 3
Vek 18 a viac · Ženy · Aktualizované 1. 10. 2026 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
- Cleveland Clinic - Cleveland /ID# 276133, Cleveland
- Cleveland Clinic - Cleveland /ID# 278273, Cleveland
- a 3 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Ženy · Aktualizované 29. 9. 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05867251ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
Prebieha náborObservačná štúdia
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT05059444Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
- Department of Subspecialty Care for Women's Health Women's Health; Division of Gynecologic Oncology, Case Comprehensive Cancer Center, Cleveland
Prebieha nábor
Vek 18 a viac · Ženy · Aktualizované 6. 8. 2026 · NCT06386887AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Blue Ash
- Research Site, Dayton
- Research Site, Sylvania
Prebieha náborFáza 3
Vek 18 a viac · Ženy · Aktualizované 21. 7. 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Miami Valley Hospital South, Centerville
Prebieha náborFáza 3
Vek 18 a viac · Ženy · Aktualizované 2. 7. 2026 · NCT06819007A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Stefanie Spielman Comprehensive Breast Center, Columbus
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 3. 2026 · NCT06395519CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus
Prebieha náborFáza 2
Vek 18 a viac · Ženy · Aktualizované 23. 12. 2025 · NCT06690775Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Cleveland Clinic, Cleveland
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 8. 2025 · NCT04429542Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.